Merck announced today that the HPS2-THRIVE ( H eart P rotection S tudy 2- T reatment of H DL to R educe the I ncidence of V ascular E vents) study did not meet its primary endpoint.
"What happened in Kenya strikes me as very likely to happen in Pakistan, and I don't know how we respond to it, " said Rep. Chris Shays, R-Connecticut.